TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06629298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5Hz Stochastic Resonance Whole-Body Vibration Training
Description: Both the experimental group and the control group performed their training on an SRT Zeptor® Medical plus noise device (Frei Swiss AG, Zurich). The device featured two independent foot plates that vibrated stochastically in all three dimensions, resulting in multidimensional movement. During the training, participants were instructed to stand on the foot plates with both feet, keep their arms relaxed at their sides, maintain a slight bend in their knees, and focus their gaze on a fixation cross on the wall. Following the protocol used in Faes et al. (2018), each training session consisted of three series, each comprising one minute of vibration training followed by one minute of rest.~The vibration frequency for the intervention group was set at 5 Hz.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 2 Hz Stochastic Resonance Whole-Body Vibration Training
Description: Both the experimental group and the control group performed their training on an SRT Zeptor® Medical plus noise device (Frei Swiss AG, Zurich). The device featured two independent foot plates that vibrated stochastically in all three dimensions, resulting in multidimensional movement. During the training, participants were instructed to stand on the foot plates with both feet, keep their arms relaxed at their sides, maintain a slight bend in their knees, and focus their gaze on a fixation cross on the wall. Following the protocol used in Faes et al. (2018), each training session consisted of three series, each comprising one minute of vibration training followed by one minute of rest.~The vibration frequency for the intervention group was set at 2 Hz.
Study: NCT05387460

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: Radiomics refers to high-throughput mining of quantitative image features from medical imaging. Radiomics derived data, when combined with other pertinent clinicopathological features, can produce accurate and robust evidence-based decision-making systems. Multimodal radiomics can provide more imaging feature information than single modal radiomics, which showed better diagnostic performance in previous study of kinds of cancer diseases.

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: Radiomics refers to high-throughput mining of quantitative image features from medical imaging. Radiomics derived data, when combined with other pertinent clinicopathological features, can produce accurate and robust evidence-based decision-making systems. Multimodal radiomics can provide more imaging feature information than single modal radiomics, which showed better diagnostic performance in previous study of kinds of cancer diseases.
Study: NCT04826887

Intervention type: OTHER
Intervention: SOLTIVE Thulium Laser
Description: Use of SOLTIVE Thulium laser for HoLEP

Intervention type: OTHER
Intervention: Standard of Care (Holmium Laser)
Description: Use of Holmium laser for HoLEP
Study: NCT06292858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMB071703 injection
Description: Intratumoral injection
Study: NCT05729399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT201
Description: Autologous tumor infiltrating lymphocyte injection
Study: NCT05109442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM24
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM24
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 840 MG in 14 ML Injection
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 840 MG in 14 ML Injection
Description: intravenous infusion
Study: NCT05146986

Intervention type: DEVICE
Intervention: Non surgical and Surgical
Description: For non-surgical group, patients will receive non-surgical treatment (analgesia and symptomatic management treatment).~For surgical group, patients will receive surgical treatment using RibFix Blu Thoracic Fixation System.

Intervention type: DEVICE
Intervention: Non surgical and Surgical
Description: For non-surgical group, patients will receive non-surgical treatment (analgesia and symptomatic management treatment).~For surgical group, patients will receive surgical treatment using RibFix Blu Thoracic Fixation System.
Study: NCT06313086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c
Description: intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab emtansine
Description: intravenous injection
Study: NCT06215183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Women applying for IUD application will receive music therapy for 5 minutes before the procedure, during the IUD application, and for 5 minutes after the procedure.
Study: NCT06329960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection combined with needle release
Description: Ultrasound-guided PIT using D5W HD for dorsal scapular nerve combined with needle release of major and minor rhomboideus
Study: NCT05853367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0472
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0472
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0472
Description: Oral Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral Administration
Study: NCT05728853

Intervention type: RADIATION
Intervention: Assessment of body composition
Description: Assessment of body composition using BIA and DXA
Study: NCT06514053

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full pulpotomy
Description: A full pulpotomy will be performed by removing the entire roof of the pulp chamber and the remaining pulp tissue will be covered by Biodentine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment
Description: The regular procedure of root canal treatment will be performed on teeth with irreversible pulpitis
Study: NCT06066346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered SC until disease progression
Study: NCT05856994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Description: For the active comparator group, the wound(s) will be cleaned and bacitracin ointment will be applied to the wound. External dressings on all treated wounds will be placed based on the current standard of care. For the control group, the wound(s) will be cleaned and a hydrocolloid Dressing will be affixed to the burn and treated area. For the treatment group, the wound(s) will be cleaned and tacrolimus (0.03%) ointment will be applied over the burn. Hydrocolloid Dressing will be affixed to the burn and treated area. External dressings on all treated wounds will be placed based on the current standard of care.
Study: NCT06157801

Intervention type: BEHAVIORAL
Intervention: Interview Study
Description: All study participants will have the following demographic information collected from their medical records:~* Sex (Male/Female/Other)~* Date of birth~* Preferred language (English/Spanish)~* Health insurance status (for example: private insurance, HCHD gold card)~* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)~* Genetic testing result (gene with pathogenic/likely pathogenic variant)~* Date of genetic testing result~* Date of documented result disclosure.

Intervention type: BEHAVIORAL
Intervention: Survey Study
Description: All study participants will have the following demographic information collected from their medical records:~* Sex (Male/Female/Other)~* Date of birth~* Preferred language (English/Spanish)~* Health insurance status (for example: private insurance, HCHD gold card)~* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)~* Genetic testing result (gene with pathogenic/likely pathogenic variant)~* Date of genetic testing result~* Date of documented result disclosure.
Study: NCT04898543

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)
Description: M-CENK will be administered up to 10 times weekly via intravenous (IV) infusion starting on study day 1 with a minimum of 7 days between each M-CENK dose. The dose of MCENK will be 0.25 - 0.75 × 10e9 cells per infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803 (Cohort 2 part B)
Description: N-803 15 μg/kg will be administered subcutaneously prior to every other dose of M-CENK for up to 5 doses of N-803.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apheresis collection of MNCs (part A)
Description: Subjects in cohort 1A will participate in apheresis collection of lymphocytes (part A) and will not receive any investigational therapy in this study.
Study: NCT06438133

Intervention type: OTHER
Intervention: CIMON
Description: The sensor assess changes in the circumference of the limb and will be applied to the lower limb before compression bandaging is applied.

Intervention type: OTHER
Intervention: Sens Motion
Description: The sensor assess physical activity and the amount of time spent at rest, standing, walking, running and count steps.
Study: NCT05497388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious Game
Description: using Serious Game for HCV education
Study: NCT06232057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Women in the intervention group will be given a pre-test (STAI) before cesarean. Then, they will be shown a relaxing video (video with nature views accompanied by nature sounds) through virtual reality glasses for a maximum of 20 minutes. After a cesarean, women's anxiety levels (STAI) will be evaluated within the first 4 hours postoperatively. Pain levels (VAS) will be assessed postoperatively at the 2nd, 4th, and 6th hours.
Study: NCT06279533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV232/Placebo
Description: Drug: LV232 15mg Group:~6 subjects will receive LV232 15mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.~Drug: LV232 25mg Group:~6 subjects will receive LV232 25mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.~Drug: LV232 40mg Group:~6 subjects will receive LV232 40mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV232
Description: Drug: LV232 15mg Group:~12 subjects will receive LV232 15mg, orally~Drug: LV232 25mg Group:~12 subjects will receive LV232 25mg, orally
Study: NCT04982692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravaginal prasterone
Description: 6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ovules
Description: Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
Study: NCT05482321

Intervention type: DRUG
Intervention: Definity Suspension for Injection
Description: * DEFINITY is administered as per manufactures instructions~* 1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX~* Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial.~* Deliver a dose of 10 μl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds.~* Following imaging, provide a 10 mL flush of preservative-free saline~* Wait at least 30minutes until second dose (if provided).

Intervention type: DRUG
Intervention: Definity Suspension for Injection
Description: * DEFINITY is administered as per manufactures instructions~* 1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX~* Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial.~* Deliver a dose of 10 μl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds.~* Following imaging, provide a 10 mL flush of preservative-free saline~* Wait at least 30minutes until second dose (if provided).

Intervention type: DRUG
Intervention: Definity Suspension for Injection
Description: * DEFINITY is administered as per manufactures instructions~* 1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX~* Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial.~* Deliver a dose of 10 μl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds.~* Following imaging, provide a 10 mL flush of preservative-free saline~* Wait at least 30minutes until second dose (if provided).
Study: NCT06649136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: comparison between oral and subcutaneous methotrexate dosis of 25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: comparison between oral and subcutaneous methotrexate dosis of 25mg
Study: NCT06647706

Intervention type: DEVICE
Intervention: Transthoracic echocardiography
Description: MPNs patients who have echocardiographic probability of PH

Intervention type: DEVICE
Intervention: Transthoracic echocardiography
Description: MPNs patients who have echocardiographic probability of PH
Study: NCT05780970

Intervention type: OTHER
Intervention: No intervention
Description: Non-treated children and caregivers complete assessments only. The primary (treated) parent / adolescent dyad participate in family based weight management treatment through the main trial. In the main trial, families are randomized to either TEENS+Parents as Coaches (parent skills training) or TEENS+Parent Weight Loss (parent behavioral weight loss).
Study: NCT06275711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic communication methods
Description: Drawing pictures, story completion, breathing and relaxation exercises
Study: NCT05874375

Intervention type: DEVICE
Group type: OTHER
Intervention: Urge stimulation
Description: Participants will receive stimulation for 60 seconds, when they feel an urgency.

Intervention type: DEVICE
Group type: OTHER
Intervention: Urge stimulation
Description: Participants will receive stimulation for 60 seconds, when they feel an urgency.

Intervention type: DEVICE
Group type: OTHER
Intervention: Time limited stimulation
Description: Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.

Intervention type: DEVICE
Group type: OTHER
Intervention: Time limited stimulation
Description: Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.
Study: NCT05116202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be administered at a dose of 3 mg/kg IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab will be administered at a dose of 1 mg/kg by IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7247669 2100 mg
Description: RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7247669 2100 mg
Description: RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7247669 2100 mg
Description: RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7247669 600 mg
Description: RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7247669 600 mg
Description: RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
Study: NCT03716843

Intervention type: OTHER
Intervention: Pressure monitoring system
Description: The pressure measurement undergarment will be given to all consenting AIS patients who have received their own thoraco-lumbo-sacral orthosis (TLSO) rigid brace. Each patient will wear the undergarment first and the TLSO brace on top. FBG sensors embedded in the undergarment will measure each pressure signal at approximately 2 minutes. The average force reading will be calculated.~Then, the experiment will be repeated once, but the anisotropic textile brace will replace the TLSO brace. The pressure measurement system will be used to obtain an accurate and adequate comparison of the forces applied to the patients. The effectiveness of the anisotropic textile brace will be evaluated through X-ray radiography, and its correction effect with be compared with that of the TLSO brace.
Study: NCT06408220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breath Test
Description: Undergo H. pylori breath test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT06374225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Titration (O2matic)
Description: The patient will receive supplemental oxygen titrated using an autonomous oxygen titration device. The patient will be monitored and vital signs documented by the site's usual SpO2 assessments, but oxygen titration will occur automatically through the O2matic PRO100 device during the intervention period, unless there is a safety concern. The SpO2 range programmed into the PRO100 is 92-94%. The acceptable SpO2 range for the protocol is 90-96%. If a patient requires \>15lpm or other signs of advancing respiratory failure, they will be taken off the autonomous oxygen and transitioned to higher flow oxygen devices or mechanical ventilation per usual clinical care. If the patient is not receiving any supplemental oxygen per the autonomous titration, the clinical team may remove the oxygen delivery device from the patient, but the patient should remain connected to the PRO100 for the duration of the intervention period for data collection and to monitor for new supplemental oxygen needs.
Study: NCT04946032

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter
Description: The epidural catheter length will vary, either 4 cm or 5 cm into the epidural space.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter
Description: The epidural catheter length will vary, either 4 cm or 5 cm into the epidural space.
Study: NCT05205343

Intervention type: OTHER
Intervention: Standard of Care
Description: complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery

Intervention type: OTHER
Intervention: Control Group
Description: complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
Study: NCT05856539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Description: ESP block is an opioid-sparing regional anesthetic involving bupivacaine and dexamethasone for lumbar spinal surgery with touted benefits including opioid use reduction and improved pain control.
Study: NCT06207149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASISTIR
Description: This will be a 24 hour advocacy program focused on adult disability services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ASISTIR
Description: This will be a 24 hour advocacy program focused on adult disability services.
Study: NCT04015791

Intervention type: OTHER
Intervention: NOCISCAN-LS Disc MR Spectroscopy
Description: The investigational Nociscan Suite is a software suite that works with existing high field MR systems and MRS pulse sequence via and optimized protocol to conduct MRS exam of lumbar discs. The software suite post-processes the NOCISCAN-LS disc MRS exam data to calculate ratios of spectroscopic signals at regions along the MRS frequency spectrum associated with certain chemicals that change with degeneration and pain

Intervention type: OTHER
Intervention: NOCISCAN-LS Disc MR Spectroscopy
Description: The investigational Nociscan Suite is a software suite that works with existing high field MR systems and MRS pulse sequence via and optimized protocol to conduct MRS exam of lumbar discs. The software suite post-processes the NOCISCAN-LS disc MRS exam data to calculate ratios of spectroscopic signals at regions along the MRS frequency spectrum associated with certain chemicals that change with degeneration and pain